Gajdács Márió, Burián Katalin, Terhes Gabriella
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös utca 6, 6720 Szeged, Hungary.
Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Dóm tér 10, 6720 Szeged, Hungary.
Antibiotics (Basel). 2019 Sep 9;8(3):143. doi: 10.3390/antibiotics8030143.
Urinary tract infections (UTIs) are one of the most common infections in the human medicine, both among outpatients and inpatients. There is an increasing appreciation for the pathogenic role of non-fermenting Gram-negative bacteria (NFGNBs) in UTIs, particularly in the presence of underlying illnesses. The study was carried out using data regarding a 10-year period (2008-2017). The antimicrobial susceptibility testing was performed using the disk diffusion method, E-tests, and broth microdilution. NFGNB represented 3.46% ± 0.93% for the outpatients, while 6.43% ± 0.81% of all positive urine samples for the inpatients ( < 0.001). In both groups, spp. (78.7% compared to 85.1%) and spp. (19.6% compared to 10.9%), were the most prevalent. The resistance levels were significantly higher in inpatients isolates ( values ranging between 0.046 and <0.001), while the differences in the resistance levels of was not as pronounced. The -lactam-resistance levels were between 15-25% and 12-28% for the and spp., respectively. 4.71% of and 1.67% of were extensively drug resistant (XDR); no colistin-resistant isolates were recovered. Increasing resistance levels of the spp. from 2013 onward, but not in the case of the spp. Although rare, the drug resistant NFGNB in UTIs present a concerning therapeutic challenge to clinicians with few therapeutic options left.
尿路感染(UTIs)是人类医学中最常见的感染之一,在门诊患者和住院患者中均是如此。人们越来越认识到非发酵革兰氏阴性菌(NFGNBs)在尿路感染中的致病作用,尤其是在存在基础疾病的情况下。该研究使用了2008年至2017年这10年期间的数据。抗菌药物敏感性试验采用纸片扩散法、E试验和肉汤微量稀释法进行。门诊患者中NFGNB占3.46%±0.93%,而住院患者所有阳性尿液样本中NFGNB占6.43%±0.81%(<0.001)。在两组中, 菌属(分别为78.7%和85.1%)和 菌属(分别为19.6%和10.9%)最为常见。住院患者分离株中的 耐药水平显著更高( 值在0.046至<0.001之间),而 耐药水平的差异则不那么明显。 菌属和 菌属的β-内酰胺耐药水平分别在15% - 25%和12% - 28%之间。 菌属的4.71%和 菌属的1.67%为广泛耐药(XDR);未分离到对黏菌素耐药的菌株。 菌属自2013年起耐药水平上升,但 菌属并非如此。虽然罕见,但尿路感染中的耐药NFGNB给临床医生带来了令人担忧的治疗挑战,可供选择的治疗方案很少。